Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Precedex, Dexmedetomidine Hydrochloride, Igalmi. Every FDA application for this active ingredient: 3 branded and 33 generic. In shortage
As of Nov 22, 2026, FDA lists 36 applications for Dexmedetomidine hydrochloride (sold as Precedex, Dexmedetomidine Hydrochloride, Igalmi), first approved Dec 17, 1999, with 7 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Bradycardia (35), Drug ineffective (21), Hypotension (16), Wrong product administered (14), Agitation (11), Product administered to patient of inappropriate age (10), Product use in unapproved indication (10), Accidental overdose (9), Cardiac arrest (7), Off label use (7)
Approvals in the EU (EMA)
First approved in the EU 141 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
PrecedexDrugs with a new indication and a new dosage for sedation of non-intubated pediatric patients during non- invasive procedures and examinations. · Pfizer Japan Inc. · Feb 24, 2023 · Review report
PrecedexDrugs with a new additional pediatric dosage indicated for sedation during artificial respiration and after weaning in patients in intensive care. · Maruishi Pharmaceutical Co., Ltd. · Nov 29, 2018
PrecedexDrugs with a new additional indication and a new dosage for sedation of non-intubated patients during surgical and other procedures under local anesthesia. · Maruishi Pharmaceutical Co., Ltd. · Jun 14, 2013
PrecedexDrugs with a new additional dosage indicated for sedation during artificial respiration and after weaning in patients in intensive care. · Maruishi Pharmaceutical Co., Ltd. · Aug 20, 2010
Approvals in Canada (Health Canada)
First approved in Canada 120 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA